# Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

> **NCT00817778** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 27 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** AZD1656
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00817778
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2012-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00817778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00817778, "Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00817778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*